Cargando…

Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial

To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd-Elsalam, Sherief, Salama, Marwa, Soliman, Shaimaa, Naguib, Ahmed Mohamed, Ibrahim, Ibrahim S., Torky, Mohamed, El Ghafar, Mohamed Samir Abd, Abdul-Baki, Enas Abdul-Raouf M., Elhendawy, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922517/
https://www.ncbi.nlm.nih.gov/pubmed/34649223
http://dx.doi.org/10.4269/ajtmh.21-0606
_version_ 1784669532045967360
author Abd-Elsalam, Sherief
Salama, Marwa
Soliman, Shaimaa
Naguib, Ahmed Mohamed
Ibrahim, Ibrahim S.
Torky, Mohamed
El Ghafar, Mohamed Samir Abd
Abdul-Baki, Enas Abdul-Raouf M.
Elhendawy, Mohammed
author_facet Abd-Elsalam, Sherief
Salama, Marwa
Soliman, Shaimaa
Naguib, Ahmed Mohamed
Ibrahim, Ibrahim S.
Torky, Mohamed
El Ghafar, Mohamed Samir Abd
Abdul-Baki, Enas Abdul-Raouf M.
Elhendawy, Mohammed
author_sort Abd-Elsalam, Sherief
collection PubMed
description To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30–60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P < 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P = 0.469). The mortality rate was comparable between the two groups (P = 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P = 0.039, 0.003, 0.001, and < 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low- and middle-income countries when other effective options are scarce.
format Online
Article
Text
id pubmed-8922517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-89225172022-03-21 Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial Abd-Elsalam, Sherief Salama, Marwa Soliman, Shaimaa Naguib, Ahmed Mohamed Ibrahim, Ibrahim S. Torky, Mohamed El Ghafar, Mohamed Samir Abd Abdul-Baki, Enas Abdul-Raouf M. Elhendawy, Mohammed Am J Trop Med Hyg Research Article To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30–60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P < 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P = 0.469). The mortality rate was comparable between the two groups (P = 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P = 0.039, 0.003, 0.001, and < 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low- and middle-income countries when other effective options are scarce. The American Society of Tropical Medicine and Hygiene 2022-03 2021-09-10 /pmc/articles/PMC8922517/ /pubmed/34649223 http://dx.doi.org/10.4269/ajtmh.21-0606 Text en © 2022 by The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Abd-Elsalam, Sherief
Salama, Marwa
Soliman, Shaimaa
Naguib, Ahmed Mohamed
Ibrahim, Ibrahim S.
Torky, Mohamed
El Ghafar, Mohamed Samir Abd
Abdul-Baki, Enas Abdul-Raouf M.
Elhendawy, Mohammed
Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title_full Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title_fullStr Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title_full_unstemmed Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title_short Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
title_sort remdesivir efficacy in covid-19 treatment: a randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922517/
https://www.ncbi.nlm.nih.gov/pubmed/34649223
http://dx.doi.org/10.4269/ajtmh.21-0606
work_keys_str_mv AT abdelsalamsherief remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT salamamarwa remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT solimanshaimaa remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT naguibahmedmohamed remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT ibrahimibrahims remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT torkymohamed remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT elghafarmohamedsamirabd remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT abdulbakienasabdulraoufm remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial
AT elhendawymohammed remdesivirefficacyincovid19treatmentarandomizedcontrolledtrial